

UCLA

UCLA Previously Published Works

Title

TCT-159 Patent Foramen Ovale Closure in Patients with Orthodeoxia-Platypnea Syndrome

Permalink

<https://escholarship.org/uc/item/3fg4b6jx>

Journal

Journal of the American College of Cardiology, 64(11)

ISSN

0735-1097

Authors

Mojadidi, Mohammad K

Gevorgyan, Rubine

Noureddin, Nabil

et al.

Publication Date

2014-09-01

DOI

10.1016/j.jacc.2014.07.196

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Congenital Heart Disease - PFO and ASD

Washington Convention Center, Lower Level, Hall A

Saturday, September 13, 2014, 5:00 PM–7:00 PM

Abstract nos: 158-163

TCT-159

Patent Foramen Ovale Closure in Patients with Orthodeoxia-Platypnea Syndrome

Mohammad K. Mojadidi¹, Rubine Gevorgyan¹, Nabil Noureddin¹, Jonathan Tobis²

¹UCLA School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, UCLA, Los Angeles, United States

Background: Orthodeoxia-platypnea syndrome (OPS) is a rare clinical condition characterized by hypoxemia in the upright position that is improved in the supine position. Although several etiologies of OPS exist, it is frequently associated with right-to-left shunting of blood at the cardiac or pulmonary level, usually via a patent foramen ovale (PFO). The aim of this study was to describe the outcomes of PFO closure in OPS. **Methods:** Patients with OPS and a PFO referred to UCLA from 2001 to 2012 who elected to have their PFO closed were assessed for the severity of their symptoms and interval SaO₂ changes, and classified according to the outcomes of “resolved,” “improved” or “no change.” The results were compared between the three groups.

Results: Of 683 patients with PFO-associated conditions, 17 (2.5%) had OPS and elected to close their PFO. Approximately a third of patients experienced complete resolution of their dyspnea and hypoxemia, requiring no supplemental oxygen use (improved SaO₂ from baseline 8.5% when recumbent and 26% when upright; p=0.03 and p< 0.0007 respectively). Another third experienced significant improvement in dyspnea, with baseline SaO₂ improved to >93% and a smaller decrease in saturation on sitting upright; they continued using supplemental oxygen (improved SaO₂ from baseline 4% when recumbent and 11% when upright, p=0.29; p=0.05 respectively). Patients with no change after PFO closure predominantly had a pulmonary etiology for their hypoxia, with elevated mean pulmonary pressures measured before closure (51.4±16.8 mmHg, p=0.06).

Variable	Resolved	Improved	No change	p-value
	Mean ± SD, or N (%)	Mean ± SD, or N (%)	Mean ± SD, or N (%)	
Total patients	6 (100%)	5 (100%)	6 (100%)	-
Age	59.9 ± 14.8	58.2 ± 12	69.3 ± 14	0.36
BMI (kg/m ²)	28.7 ± 6.8	31.6 ± 4.5	29.1 ± 7.6	0.74
SaO ₂ resting (% , pre-procedure)	89.2 ± 7.1	90.7 ± 7.1	83.2 ± 5.4	0.31
SaO ₂ in the upright position (% , pre-procedure)	75.7 ± 5.9	76.7 ± 4.9	76 ± 6.9	0.98
PFO canal height on cath (mm)	10.3 ± 3.2	8.5 ± 3.1	11.5 ± 4.9	0.61
Presence of atrial septal aneurysm	0 (0%)	1 (20%)	2 (33.3%)	0.47
Presence of residual shunt	1 (16.7%)	1 (20%)	2 (33.3%)	0.47
SaO ₂ resting (% , post-procedure)	96.8 ± 1.9	94.4 ± 1.5	87.2 ± 3.5	<0.0001
SaO ₂ in the upright position (% , post-procedure)	95.8 ± 2.8	87.6 ± 9.3	78.5 ± 4.9	0.033
Mean pulmonary pressure (mm Hg, pre-cath)	32.3 ± 16.5	26.4 ± 8.8	51.4 ± 16.8	0.06

Conclusions: PFO closure may resolve symptomatic postural dyspnea and hypoxemia and is an effective method for treating OPS.